1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Equipment & Services
Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited

BALAXI.NS
Balaxi Pharmaceuticals LimitedIN flagNational Stock Exchange of India
23.85
INR
-0.15
- -
265.53MMarket Cap

Total Valuation

Balaxi Pharmaceuticals Limited carries a market capitalization of 265.53M, placing it among publicly traded companies globally. Its enterprise value stands at 1.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap265.53M
Enterprise Value1.28B

Share Statistics

Balaxi Pharmaceuticals Limited currently has 55.21M shares outstanding.

Shares Outstanding55.21M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Balaxi Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 59.95. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 7.69.

PE Ratio59.95
PS Ratio0.31
PB Ratio7.69
P/TBV Ratio0.39
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Balaxi Pharmaceuticals Limited trades at an EV/EBITDA multiple of 20.08 and an EV/FCF ratio of 122.50. The EV/Sales ratio of 0.47 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.08 provides insight into valuation relative to core operating earnings.

EV / Sales0.47
EV / EBITDA20.08
EV / EBIT20.08
EV / FCF122.50

Financial Position

Balaxi Pharmaceuticals Limited maintains a current ratio of 4.05, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.15, indicating elevated leverage, while an interest coverage ratio of 1.63 demonstrates limited ability to service its debt obligations.

Current Ratio4.05
Quick Ratio0.23
Debt / Equity23.15
Debt / EBITDA9.04
Interest Coverage1.63

Financial Efficiency

Balaxi Pharmaceuticals Limited posts a return on equity of 1.53 and a return on invested capital of 0.57.

Return on Equity (ROE)1.53
Return on Assets (ROA)0.44
Return on Invested Capital (ROIC)0.57
Return on Capital Employed (ROCE)1.66
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.86

Taxes

Over the trailing twelve months, Balaxi Pharmaceuticals Limited has paid 38.76M in income taxes, reflecting an effective tax rate of 73.23.

Income Tax38.76M
Effective Tax Rate73.23

Stock Price Statistics

Balaxi Pharmaceuticals Limited's stock has declined approximately -51.29671% over the past 52 weeks. The 50-day moving average sits at 25.02, while the 200-day moving average is 28.51.

Beta (5Y)N/A
52-Week Price Change-51.29671%
50-Day Moving Average25.02
200-Day Moving Average28.51
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Balaxi Pharmaceuticals Limited generated 2.70B in revenue and converted that into 14.17M in net income, yielding earnings per share of 0.26. EBITDA reached 63.75M, while operating income came in at 63.75M.

Revenue2.70B
Gross Profit1.19B
Operating Income63.75M
Pretax Income52.93M
Net Income14.17M
EBITDA63.75M
EBIT63.75M
Earnings Per Share (EPS)0.26

Balance Sheet

Balaxi Pharmaceuticals Limited holds 145.59M in cash and equivalents against 576.49M in total debt, resulting in a net debt position of 412.31M. Total book value stands at 110.42M, with working capital of 1.89B providing operational flexibility.

Cash & Cash Equivalents145.59M
Total Debt576.49M
Net Debt412.31M
Equity (Book Value)110.42M
Book Value Per Share2.04
Working Capital1.89B

Margins

Balaxi Pharmaceuticals Limited operates with a gross margin of 44.16, reflecting its pricing power and cost economics. The operating margin of 2.36 and net profit margin of 0.52 provide insight into operational efficiency.

Gross Margin44.16
Operating Margin2.36
Pretax Margin1.96
Profit Margin0.52
EBITDA Margin2.36

Stock Splits

Balaxi Pharmaceuticals Limited's most recent stock split took place on May 30, 2024 with a 1:5 split ratio.

Last Split Date5/30/2024
Split Ratio1:5

Scores

Balaxi Pharmaceuticals Limited posts an Altman Z-Score of 2.28, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.28